Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VNDABullishIndustry Newsnews

High materiality8/10

Vanda Advances Tasimelteon for DSWPD with Positive Phase III topline

Sep 29, 2026, 7:22 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive top-line Phase III results and a clear regulatory path to an sNDA can unlock upside, especially if FDA approves DSWPD indication; however, small trial size introduces execution risk and regulatory uncertainty, tempering upside.

AI summary

What happened, with direct paths to the underlying reporting

Vanda reported positive Phase III topline results for tasimelteon in Delayed Sleep-Wake Phase Disorder, meeting the primary endpoint and showing a 37.1-minute earlier sleep onset versus placebo. The company plans to submit a supplemental NDA to the FDA, potentially making HETLIOZ the first approved treatment for DSWPD, expanding its circadian-regulator franchise and creating a new growth avenue if approved.

Phase III tasimelteon met primary endpoint in DSWPD trial.
Sleep onset shifted 37.1 minutes earlier vs placebo (p=0.022).
60% (12/20) achieved ≥30-minute advance vs 15% (3/20) in placebo.
Vanda plans an sNDA submission with FDA for DSWPD.
DSWPD prevalence in adults estimated 0.2%-1.5% (0.5–4.1 million US).

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Vanda Advances Tasimelteon for DSWPD with Positive Phase III topline

Vanda Pharmaceuticals Soars After FDA Approves Bysanti Treatment

VNDA Soars After FDA Approval for Bysanti in Mental Health Treatments

US FDA approves Vanda's psychiatric drug

US FDA approves Vanda Pharmaceuticals' motion sickness drug